PYIs Prosper, but Program Falls Short

WASHINGTON—The Presidential Young Investigators award program is supposed to lure newly minted scientists and engineers away from industry and into academia by offering them up to $100,000 a year for their research. The 200 young scientists chosen each year by the National Science Foundation are also asked, somewhat paradoxically, to build ties with industry by obtaining matching funds for the federal dollars they receive. But four years after it was begun, the PYI program has failed

Written byElisabeth Carpenter
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

WASHINGTON—The Presidential Young Investigators award program is supposed to lure newly minted scientists and engineers away from industry and into academia by offering them up to $100,000 a year for their research. The 200 young scientists chosen each year by the National Science Foundation are also asked, somewhat paradoxically, to build ties with industry by obtaining matching funds for the federal dollars they receive.

But four years after it was begun, the PYI program has failed to achieve either goal. The awards have had little effect on the career decisions of the young investigators, who are chosen only after they have accepted tenure-track university positions.

Moreover, the program has had mixed success in creating closer ties between academia and industry. The ability of scientists to obtain up to $37,500 from industry to match the NSF funds varies greatly by field. Engineers do best, obtaining 80 percent or more of the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies